Computational and Mathematical Methods in Medicine / 2021 / Article / Tab 3 / Review Article
[Retracted] Second-Generation Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia Patients with Stable Deep Molecular Response: A Systematic Review and a Meta-Analysis Table 3 Subgroup analysis of factors affecting recurrence.
Characteristics Grouping ES (95% CI) Sample size ( ≤78 0.56 (0.44-0.67) 64.4% >78 0.51 (0.45-0.56) 0% Overall 0.53 (0.47-0.60) 47.1% Female (%) ≤49.5 0.52 (0.42-0.62) 65.9% >49.5 0.56 (0.48-0.63) 0% Overall 0.53 (0.47-0.60) 47.1% Age (years) ≤56 0.54 (0.46-0.61) 51.6% >56 0.52 (0.36-0.68) 70.5% Overall 0.53 (0.47-0.60) 47.1% Previous therapy IFN/Ima 0.61 (0.53-0.70) 0% Ima 0.49 (0.44-0.55) 0% Overall 0.53 (0.47-0.60) 47.1% Dasa or Nilo Dasa 0.52 (0.36-0.68) 70.5% Nilo 0.54 (0.46-0.61) 51.6% Overall 0.53 (0.47-0.60) 47.1% 2G-TKI median duration (month) ≤31 0.52 (0.42-0.62) 65.9% >31 0.56 (0.48-0.63) 0% Overall 0.53 (0.47-0.60) 47.1% Low Sokal score ≤54.5 0.53 (0.43-0.64) 58.2% >54.4 0.54 (0.35-0.72) 80.0% Overall 0.53 (0.47-0.60) 47.1% International or national International 0.51 (0.45-0.56) 0% National 0.56 (0.44-0.67) 64.4% Overall 0.53 (0.47-0.60) 47.1% Quality assessment H 0.54 (0.46-0.61) 51.6% L 0.52 (0.36-0.68) 70.5% Overall 0.53 (0.47-0.60) 47.1%
